A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Angioblast Systems
ClinicalTrials.gov Identifier:
NCT00721045
First received: July 21, 2008
Last updated: January 14, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2013
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)